Tarsus Pharmaceuticals, INC 8-K filings

Tarsus Pharmaceuticals announced robust second quarter 2026 financial results, with XDEMVY net sales surging 69% year-over-year, leading to an increased full-year sales forecast and strategic pipeline expansion.

Tarsus Pharmaceuticals announced a $125 million private placement equity financing, including common stock and pre-funded warrants, to fund clinical development and commercial activities.

Tarsus Pharmaceuticals announced a definitive agreement to acquire Alkeus Pharmaceuticals for approximately $450 million, bolstering its eye care pipeline with gildeuretinol for Stargardt disease.

Tarsus Pharmaceuticals announced the departure of its Chief Commercial Officer, Aziz Mottiwala, who is leaving to become CEO of a public medical device company.

Tarsus Pharmaceuticals has acquired iRenix Medical, gaining late-stage asset IRX-101 for $75 million to enhance its eye care portfolio.

Tarsus Pharmaceuticals, Inc. announced the results of its Annual Meeting of Stockholders held on June 25, 2026, including the election of directors and ratification of its independent auditor.

Tarsus Pharmaceuticals reported robust first-quarter 2026 financial results, driven by significant year-over-year growth in XDEMVY net product sales and progress across its pipeline.

Tarsus Pharmaceuticals reported strong full-year 2025 financial results, driven by significant XDEMVY sales growth, and outlined plans for pipeline expansion.

Tarsus Pharmaceuticals, Inc. published a corporate presentation highlighting strong XDEMVY sales, pipeline expansion, and future growth strategies.

Tarsus Pharmaceuticals reported robust third-quarter 2025 financial results, driven by significant growth in XDEMVY net sales and a reduced net loss, while advancing its pipeline.

Tarsus Pharmaceuticals reports record Q2 2025 net product sales of $102.7 million for XDEMVY, significantly reducing net loss and expanding its prescriber base.

Tarsus Pharmaceuticals, Inc. announced that its stockholders approved all four proposals, including the election of two Class II directors and the ratification of Ernst & Young LLP, at its Annual Meeting held on June 12, 2025.

Tarsus Pharmaceuticals announces a successful first quarter in 2025, highlighted by a 217% year-over-year increase in XDEMVY net product sales and a strengthened financial position following a public equity offering.

Tarsus Pharmaceuticals successfully closes a public offering, generating approximately $134.8 million in net proceeds after the underwriters fully exercised their option to purchase additional shares.

Tarsus Pharmaceuticals has priced an upsized public offering of 2,808,988 shares of common stock at $44.50 per share, expecting gross proceeds of approximately $125 million.

Tarsus Pharmaceuticals announces robust financial results for Q4 and full-year 2024, fueled by strong sales of XDEMVY and advancements in its pipeline.

Tarsus Pharmaceuticals reports the resignation of Rosemary Crane from the Board of Directors, effective January 17, 2025, and subsequent appointment as a consultant, along with other board committee changes.

Tarsus Pharmaceuticals is rapidly growing its eye care business, highlighted by the successful launch of XDEMVY for Demodex blepharitis and the development of new treatments for ocular rosacea and Lyme disease.

Tarsus Pharmaceuticals has entered into a 120-month lease agreement for a new corporate headquarters in Irvine, California, with a total of 59,626 square feet of office space.

Tarsus Pharmaceuticals announced a successful third quarter of 2024, highlighted by $48.1 million in net product sales of XDEMVY and significant progress in payer coverage.

Tarsus Pharmaceuticals has appointed Elizabeth Yeu as its new Chief Medical Officer, effective November 4, 2024, following her resignation from the company's board of directors.

Tarsus Pharmaceuticals announced a 65% increase in XDEMVY net product sales in Q2 2024 compared to Q1 2024, reaching $40.8 million.

Tarsus Pharmaceuticals held its annual meeting on June 13, 2024, where stockholders elected two Class I directors and ratified the appointment of Ernst & Young LLP as the company's independent auditor.

Tarsus Pharmaceuticals reported a significant increase in XDEMVY sales and expanded payer coverage in the first quarter of 2024, alongside a strengthened financial position.

Tarsus Pharmaceuticals has secured a $200 million non-dilutive financing commitment from Pharmakon Advisors, refinancing existing debt and providing capital for general corporate purposes.

Tarsus Pharmaceuticals successfully closed a public offering, raising approximately $107.8 million through the sale of common stock and pre-funded warrants.

Tarsus Pharmaceuticals has announced a $100 million public offering of common stock and pre-funded warrants, with an option for underwriters to purchase additional shares.

Tarsus Pharmaceuticals announced strong fourth quarter and full-year 2023 financial results, highlighted by the successful launch of XDEMVY and positive clinical trial results across its pipeline.

Tarsus Pharmaceuticals' Chief Medical Officer, Jose Trevejo, M.D., Ph.D., will depart from his role effective January 18, 2024, and his employment on February 17, 2024.